Netherlands vs Qatar: Reported rate of new cervical cancer cases
Netherlands
6.93 per 100,000 women
in 2017
Qatar
8.72 per 100,000 women
in 2017
Netherlands rank
26th
Qatar rank
23rd
Reported rate of new cervical cancer cases over time
- Netherlands
- Qatar
How they compare
Qatar currently reports 8.72 per 100,000 women against 6.93 per 100,000 women in Netherlands, a difference of 1.79 per 100,000 women.
That makes Qatar's figure about 1.3 times Netherlands's.
The two have swapped places 8 times across 15 shared years of data; in 2003 it was Qatar ahead.
Netherlands ranks 26th and Qatar ranks 23rd of 46 countries.
Netherlands has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Netherlands | Qatar | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.92 per 100,000 women | 5.82 per 100,000 women | 0.1079 per 100,000 women | Netherlands |
| 2010s | 6.54 per 100,000 women | 4.35 per 100,000 women | 2.19 per 100,000 women | Netherlands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher reported rate of new cervical cancer cases, Netherlands or Qatar?
- Qatar, at 8.72 per 100,000 women against 6.93 per 100,000 women in Netherlands as of 2017.
- What is the difference in reported rate of new cervical cancer cases between Netherlands and Qatar?
- 1.79 per 100,000 women, with Qatar ahead.
- How many years of comparable data are there for Netherlands and Qatar?
- 15 years are reported by both, from 2003 to 2017.
- How do Netherlands and Qatar rank globally for reported rate of new cervical cancer cases?
- Netherlands ranks 26th and Qatar ranks 23rd of 46 countries.
- Where does this data come from?
- Global Cancer Observatory (2025) – processed by Our World in Data, published as Reported rate of new cervical cancer cases. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Reported number of new cervical cancer cases per 100,000 women, based on data from cancer registries. Comparisons may be affected by differences in measurement, including screening and diagnosis.